Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

Teva Pharmaceutical Industries Limited develops ... OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as ...

Teva collaboration agreement aims to accelerate clinical data generation for TEV-56278 and develop Anti-PD1-IL2 Therapy.

Teva Pharmaceutical has announced a collaboration with Shanghai Fosun Pharmaceutical (Fosun Pharma) to advance the global ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Companies like Tailor Brands can help you turn your business idea into a reality. Established in 2015, Tailor Brands can kick-start and manage your growing business. We at the MarketWatch Guides ...

Teva's announcement of the tentative settlement came amid its second-quarter results update, which revealed a 3% reduction in revenues to $3.8 billion compared to the same period of 2021, with a ...

1 Day TEVA -4.07% DJIA -1.79% S&P 500 -1.13% Health Care/Life Sciences 0.85% ...